Oral Session 1-10D MM: Daratumumab

[OS1-10D-2] Daratumumab plus Rd in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma

Kenshi Suzuki¹, Shinsuke Iida², Hirohiko Shibayama³, Hidehisa Noguchi⁴, Hiroshi Yamazaki⁴, Hiromi Koga⁴, Hiroyuki Takamatsu⁵ (1.Japanese Red Cross Medical center, Tokyo, Japan, 2.Hematol.&Oncol. Nagoya City University, Nagoya, Japan, 3.Osaka Univ. Grad. Schl. Med., Osaka, Japan, 4.Janssen Pharmaceutical K.K. , Tokyo, Japan, 5.Hematology/Respiratory Medicine, Kanazawa Univ., Kanazawa, Japan)